A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics

NCT01833923 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: anlotinib

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Collaborators

[object Object]